So the field is using plasma markers, which is incredible that we can now measure amyloid pathology in the brain based on a simple blood draw. But Alzheimer’s disease is so molecularly complex and we have just scratched the surface of what we know. And I think we need to keep performing lumbar punctures and collecting CSF because this is, in my view, the only way that we can really learn more of the molecular mechanisms that are ongoing at this moment in a particular patient...
So the field is using plasma markers, which is incredible that we can now measure amyloid pathology in the brain based on a simple blood draw. But Alzheimer’s disease is so molecularly complex and we have just scratched the surface of what we know. And I think we need to keep performing lumbar punctures and collecting CSF because this is, in my view, the only way that we can really learn more of the molecular mechanisms that are ongoing at this moment in a particular patient. And also this will help us to learn in trials, for example, when you have an intervention, what the intervention is doing, for whom it might work, and why it would not work for another person. So I say keep collecting CSF.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
